Posted by Michael Wonder on 23 May 2024
Jiangsu to ‘reapply for US approval of rivoceranib combo therapy ASAP’
23 May 2024 - Hangseo Hengrui Pharmaceuticals said Thursday that it would meet with the US FDA as soon as possible to reapply for approval of rivoceranib and camrelizumab combination therapy for treating liver cancer.
Hangseo Hengrui Pharmaceuticals Vice President Frank Jiang said so at the Second Bio Forum, which was organised by the HLB Group and focused on the R&D and commercialisation of liver cancer drugs.
